ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California. Show more

240 E. GRAND AVE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, 2Nd Floor, South San Francisco, CA, 94080, USA

https://www.oricpharma.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

1.333B

52 Wk Range

$7.23 - $14.93

Previous Close

$12.74

Open

$12.51

Volume

991,453

Day Range

$12.51 - $12.99

Enterprise Value

1.076B

Cash

37.48M

Avg Qtr Burn

-31.61M

Insider Ownership

1.59%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ORIC-944 + ERLEADA® (apalutamide) and NUBEQA® (darolutamide) Details Metastatic castration-resistant prostate cancer (mCRPC)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) Details Solid tumor/s, Advanced malignancies, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) + amivantamab SC Details 1L Non-small cell lung carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) Details Cancer, 1L Non-small cell lung carcinoma	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enozertinib (ORIC-114) Details 2L Non-small cell lung carcinoma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-533 Details Multiple myeloma, Cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 + Xtandi (enzalutamide) Details Prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ORIC-101 and nab-paclitaxel Details Solid tumor/s, Muscle control disorder, Spasticity, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.